Martenson J A, Gunderson L L
Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905.
Cancer. 1993 Mar 1;71(5):1736-40. doi: 10.1002/1097-0142(19930301)71:5<1736::aid-cncr2820710506>3.0.co;2-f.
Most therapeutic regimens currently in use for sphincter preservation in anal cancer utilize combined radiation therapy and chemotherapy. To provide a basis for comparison with combined therapy results, an analysis was made of patients treated with external radiation therapy without chemotherapy.
Eighteen patients with squamous cell, basaloid, or cloacogenic carcinoma of the anal canal were treated with external radiation therapy between January 1, 1980, and December 31, 1989, with the goal of sphincter preservation and cure. Before radiation therapy, five patients had incisional biopsies, two underwent piecemeal removal of the tumor, three had excisional biopsies with positive margins, five had excisional biopsies with negative margins, and three had excisional biopsies with unknown margins. All patients received 45 to 50 Gy in 25 to 28 fractions to the pelvis and perineum, and 16 of the 18 received an additional boost to the primary site to bring the total dose to 55 to 67 Gy in 30 to 38 fractions.
With follow-up of 2.5 to 11.2 years in surviving patients, 5-year projected survival and freedom from local recurrence were 94% and 100%, respectively. Two patients required a temporary colostomy because of treatment complications. No patient required a permanent colostomy or had permanent loss of anal sphincter function as a result of local recurrence or complications.
These results, combined with others, suggest that external radiation therapy without chemotherapy is an acceptable alternative to combined radiation therapy and chemotherapy in the management of anal cancer.
目前用于肛管癌保留括约肌的大多数治疗方案采用放射治疗和化疗相结合的方法。为了提供与联合治疗结果进行比较的依据,对未接受化疗而仅接受外照射治疗的患者进行了分析。
1980年1月1日至1989年12月31日期间,18例患有肛管鳞状细胞癌、基底样癌或泄殖腔源癌的患者接受了外照射治疗,目的是保留括约肌并治愈疾病。放疗前,5例患者进行了切开活检,2例进行了肿瘤的碎块切除,3例进行了切缘阳性的切除活检,5例进行了切缘阴性的切除活检,3例进行了切缘情况不明的切除活检。所有患者盆腔和会阴接受25至28次分割、总量45至50 Gy的照射,18例患者中有16例对原发部位进行了追加照射,使总剂量达到30至38次分割、55至67 Gy。
存活患者的随访时间为2.5至11.2年,预计5年生存率和无局部复发生存率分别为94%和100%。2例患者因治疗并发症需要临时结肠造口术。没有患者因局部复发或并发症而需要永久性结肠造口术或出现肛门括约肌功能永久性丧失。
这些结果以及其他研究结果表明,在肛管癌的治疗中,不进行化疗的外照射治疗是放射治疗和化疗联合治疗的一种可接受的替代方法。